Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HPT021
MIFTS: 65

Hepatitis

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Nephrological diseases, Oral diseases, Rare diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Hepatitis

About this section

MalaCards integrated aliases for Hepatitis:

Name: Hepatitis 11 75 28 53 5 41 14 36 71
Chronic Persistent Hepatitis 11 53 71
Chronic Hepatitis 11 14 16
Hepatitis, Chronic 43 71
Acute Hepatitis 11 71
Acute and Subacute Liver Necrosis 11
Other Specified Chronic Hepatitis 33
Chronic Persistent Hepatitis Nec 33
Acute/subac. Necrosis of Liver 11
Hepatitis Due to Toxoplasmosis 33
Chronic Hepatitis, Unspecified 33
Chronic Lobular Hepatitis Nec 33
Chronic Active Hepatitis Nec 33
Hepatitis in Toxoplasmosis 33
Toxoplasmal Hepatitis 33
Hepatitis Chronic 53
Hepatitis, Animal 71
Animal Hepatitis 11
Hepatitis a 71

Classifications:

MalaCards categories:
Global: Infectious diseases Genetic diseases Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases Liver diseases Immune diseases Nephrological diseases Oral diseases
See all MalaCards categories (disease lists)
ICD10: 31
ICD11: 33


External Ids:

Disease Ontology 11 DOID:2237
ICD9CM 34 570 571.4 571.41
MeSH 43 D006521
NCIt 49 C82978
ICD10 31 K73 K73.0 K73.9
UMLS 71 C0001308 C0019158 C0019159 more
Sources

Summaries for Hepatitis

About this section

MedlinePlus: 41 What is hepatitis? Hepatitis is inflammation of the liver. Inflammation is swelling that happens when tissues of the body are injured or infected. It can damage your liver. This swelling and damage can affect how well your liver functions. Hepatitis can be an acute (short-term) infection or a chronic (long-term) infection. Some types of hepatitis cause only acute infections. Other types can cause both acute and chronic infections. What causes hepatitis? There are different types of hepatitis, with different causes: Viral hepatitis is the most common type. It is caused by one of several viruses -- hepatitis viruses A, B, C, D, and E. In the United States, A, B, and C are the most common. Alcoholic hepatitis is caused by heavy alcohol use Toxic hepatitis can be caused by certain poisons, chemicals, medicines, or supplements Autoimmune hepatitis is a chronic type in which your body's immune system attacks your liver. The cause is not known, but genetics and your environment may play a role. How is viral hepatitis spread? Hepatitis A and hepatitis E usually spread through contact with food or water that was contaminated with an infected person's stool. You can also get hepatitis E by eating undercooked pork, deer, or shellfish. Hepatitis B, hepatitis C, and hepatitis D spread through contact with the blood of someone who has the disease. Hepatitis B and D may also spread through contact with other body fluids. This can happen in many ways, such as sharing drug needles or having unprotected sex. Who is at risk for hepatitis? The risks are different for the different types of hepatitis. For example, with most of the viral types, your risk is higher if you have unprotected sex. People who drink a lot over long periods of time are at risk for alcoholic hepatitis. What are the symptoms of hepatitis? Some people with hepatitis do not have symptoms and do not know they are infected. If you do have symptoms, they may include: Fever Fatigue Loss of appetite Nausea and/or vomiting Abdominal pain Dark urine Clay-colored bowel movements Joint pain Jaundice, yellowing of your skin and eyes If you have an acute infection, your symptoms can start anywhere between 2 weeks to 6 months after you got infected. If you have a chronic infection, you may not have symptoms until many years later. What other problems can hepatitis cause? Chronic hepatitis can lead to complications such as cirrhosis (scarring of the liver), liver failure, and liver cancer. Early diagnosis and treatment of chronic hepatitis may prevent these complications. How is hepatitis diagnosed? To diagnose hepatitis, your health care provider: Will ask about your symptoms and medical history Will do a physical exam Will likely do blood tests, including tests for viral hepatitis Might do imaging tests, such as an ultrasound, CT scan, or MRI May need to do a liver biopsy to get a clear diagnosis and check for liver damage What are the treatments for hepatitis? Treatment for hepatitis depends on which type you have and whether it is acute or chronic. Acute viral hepatitis often goes away on its own. To feel better, you may just need to rest and get enough fluids. But in some cases, it may be more serious. You might even need treatment in a hospital. There are different medicines to treat the different chronic types of hepatitis. Possible other treatments may include surgery and other medical procedures. People who have alcoholic hepatitis need to stop drinking. If your chronic hepatitis leads to liver failure or liver cancer, you may need a liver transplant. Can hepatitis be prevented? There are different ways to prevent or lower your risk for hepatitis, depending on the type of hepatitis. For example, not drinking too much alcohol can prevent alcoholic hepatitis. There are vaccines to prevent hepatitis A and B. Autoimmune hepatitis cannot be prevented. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary: Hepatitis, also known as chronic persistent hepatitis, is related to hepatitis c and hepatitis a, and has symptoms including nausea and vomiting, constipation and fever. An important gene associated with Hepatitis is HAVCR1 (Hepatitis A Virus Cellular Receptor 1), and among its related pathways/superpathways are Toll-like receptor signaling pathway and Ebola virus infection in host. The drugs Glycyrrhizic acid and Acarbose have been mentioned in the context of this disorder. Affiliated tissues include liver, kidney and t cells, and related phenotype is mortality/aging.

Wikipedia: 75 Hepatitis is inflammation of the liver tissue. Some people or animals with hepatitis have no symptoms,... more...
Sources

Related Diseases for Hepatitis

About this section

Diseases in the Hepatitis family:

Hepatitis C Virus Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis B Hepatitis D
Autoimmune Hepatitis Hepatitis E
Autoimmune Hepatitis Type 2 Autoimmune Hepatitis Type 1

Diseases related to Hepatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2687)
# Related Disease Score Top Affiliating Genes
1 hepatitis c 33.7 SLC17A5 SCARB1 PSMA7 IFNA2 IFNA1 GPT
2 hepatitis a 33.6 IFNA2 IFNA1 HAVCR2 HAVCR1 GPT F2
3 viral hepatitis 33.6 SLC17A5 SEPSECS IFNA2 IFNA1 GPT F2
4 hepatitis b 33.6 SLC17A5 SLC10A1 RSF1 PSMA7 NR5A2 LAMTOR5
5 hepatitis c virus 33.5 SCARB1 PSMA7 HAVCR2 GPT DDX3X CLEC4M
6 hepatitis d 33.5 SLC10A1 IFNA2 IFNA1 GPT
7 autoimmune hepatitis 33.5 SLC17A5 SEPSECS GPT F2 ASGR2
8 alcoholic hepatitis 33.3 SLC17A5 GPT F2
9 viral infectious disease 33.0 SLC17A5 IFNA2 IFNA1 GPT CLEC4M
10 liver cirrhosis 32.9 SLC17A5 IFNA1 GPT F2 ASGR2 AFP
11 liver disease 32.9 SLC17A5 SLC10A1 SEPSECS IFNA2 IFNA1 GPT
12 drug-induced hepatitis 32.9 SEPSECS GPT F2 AFP
13 cryoglobulinemia, familial mixed 32.5 IFNA2 IFNA1
14 cryoglobulinemia 32.2 IFNA2 IFNA1 GPT
15 cholestasis 32.1 SLC17A5 SLC10A1 GPT F2
16 alcohol use disorder 32.1 SLC17A5 GPT F2 AFP
17 hepatic encephalopathy 32.0 SLC17A5 GPT F2
18 primary biliary cholangitis 32.0 SLC17A5 SLC10A1 SEPSECS GPT F2 AFP
19 deficiency anemia 32.0 PSMA7 IFNA2 IFNA1 GPT F2
20 portal hypertension 31.9 SLC17A5 GPT F2 AFP
21 exanthem 31.9 IFNA1 GPT F2
22 alcoholic liver cirrhosis 31.9 GPT F2 AFP
23 thrombocytopenia 31.9 SLC17A5 IFNA2 IFNA1 HAVCR2 HAVCR1 GPT
24 non-alcoholic steatohepatitis 31.8 SCARB1 GPT AFP
25 bilirubin metabolic disorder 31.8 SLC17A5 SLC10A1 GPT F2 AFP
26 hypothyroidism 31.7 IFNA2 IFNA1 GPT F2 AFP
27 sclerosing cholangitis 31.7 SLC10A1 SEPSECS GPT F2 AFP
28 cholangitis, primary sclerosing 31.7 SLC10A1 SEPSECS GPT F2 AFP
29 substance abuse 31.7 GPT F2 AFP
30 acute kidney failure 31.7 HAVCR1 GPT F2
31 esophageal varix 31.7 GPT F2 AFP
32 hepatic coma 31.6 GPT F2 AFP
33 chickenpox 31.6 IFNA1 GPT F2
34 hepatorenal syndrome 31.6 HAVCR1 GPT F2 AFP
35 obstructive jaundice 31.6 SLC17A5 GPT F2 AFP
36 biliary atresia 31.5 SLC10A1 GPT F2
37 intrahepatic cholestasis 31.5 SLC17A5 GPT AFP
38 portal vein thrombosis 31.4 GPT F2 AFP
39 severe acute respiratory syndrome 31.4 IFNA1 GPT CLEC4M
40 hypersplenism 31.3 GPT F2 AFP
41 alpha-1-antitrypsin deficiency 31.3 SEPSECS GPT F2 AFP
42 malaria 31.1 SCARB1 IFNA2 IFNA1 HAVCR2 GPT F2
43 acalculous cholecystitis 31.1 GPT F2
44 urinary tract infection 31.1 HAVCR1 GPT F2
45 budd-chiari syndrome 31.0 GPT F2 AFP
46 severe covid-19 31.0 IFNA2 IFNA1 GPT F2
47 intrahepatic cholestasis of pregnancy 31.0 SLC10A1 NR5A2 GPT
48 dengue hemorrhagic fever 30.9 IFNA1 GPT CLEC4M
49 hemoglobinopathy 30.7 PSMA7 GPT F2
50 scrub typhus 30.7 SLC17A5 HAVCR1 GPT

Comorbidity relations with Hepatitis via Phenotypic Disease Network (PDN): (show all 14)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Acute Pancreatitis
Cholangitis Deficiency Anemia
Esophagitis Familial Atrial Fibrillation
Heart Disease Hepatic Encephalopathy
Hypothyroidism Mitral Valve Disease
Portal Hypertension Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Hepatitis:



Diseases related to Hepatitis
Sources

Symptoms & Phenotypes for Hepatitis

About this section

UMLS symptoms related to Hepatitis:


nausea and vomiting; constipation; fever; abdominal pain; pruritus; diarrhea; hepatosplenomegaly; dyspepsia; lameness, animal; icterus; heartburn; gastrointestinal gas; hepatocellular jaundice

GenomeRNAi Phenotypes related to Hepatitis according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.17 AFP ASGR2 CCDC85B CLEC4M DDX3X F2
2 no effect GR00402-S-2 10.17 ASGR2 CCDC85B CLEC4M DDX3X F2 HAVCR1

MGI Mouse Phenotypes related to Hepatitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 mortality/aging MP:0010768 9.47 ASGR2 CLEC4M DDX3X F2 HAVCR1 HAVCR2
Sources

Drugs & Therapeutics for Hepatitis

About this section

Drugs for Hepatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 583)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Glycyrrhizic acid Approved, Experimental Phase 4 1405-86-3 3495 14982
2
Acarbose Approved, Investigational Phase 4 56180-94-0 441184 444254
3
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
4
Lenograstim Approved, Investigational Phase 4 135968-09-1
5
Rituximab Approved Phase 4 174722-31-7
6
Alprostadil Approved, Investigational Phase 4 745-65-3 5280723
7
Framycetin Approved, Experimental, Vet_approved Phase 4 1404-04-2, 119-04-0, 3947-65-7 413349 8378
8
Chlorhexidine Approved, Vet_approved, Withdrawn Phase 4 55-56-1 2713 9552079
9
Ethanol Approved Phase 4 64-17-5 702
10
Milk thistle Approved, Experimental, Investigational Phase 4 65666-07-1
11
Nevirapine Approved Phase 4 129618-40-2 4463
12
Zidovudine Approved Phase 4 30516-87-1 35370
13
Fosamprenavir Approved Phase 4 226700-79-4 131536
14
Nitazoxanide Approved, Investigational, Vet_approved Phase 4 55981-09-4 41684
15
Simethicone Approved Phase 4 8050-81-5
16
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
17
Colchicine Approved Phase 4 64-86-8 2833 6167
18
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
19
Promethazine Approved, Investigational Phase 4 60-87-7 4927
20
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
21
Aluminum sulfate Approved Phase 4 10043-01-3
22
Aluminum hydroxide Approved, Investigational Phase 4 21645-51-2
23
Losartan Approved Phase 4 114798-26-4 3961
24
Iron Approved Phase 4 7439-89-6 29936
25
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
26
Citalopram Approved Phase 4 59729-32-7, 59729-33-8 2771
27
Cobicistat Approved Phase 4 1004316-88-4 24950485 25151504
28
Elvitegravir Approved Phase 4 697761-98-1 23083982 5277135
29
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
30
Chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
31
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
32
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030
33
Didanosine Approved Phase 4 69655-05-6 50599
34
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
35
Nelfinavir Approved Phase 4 159989-64-7 64143
36
Acetylcarnitine Approved, Investigational Phase 4 3040-38-8
37
Edetate calcium disodium anhydrous Approved, Vet_approved Phase 4 62-33-9, 60-00-4 6049
38
Pentetic acid Approved Phase 4 67-43-6
39
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
40
Meperidine Approved Phase 4 57-42-1 4058
41
Baclofen Approved Phase 4 1134-47-0 2284
42
Empagliflozin Approved Phase 4 864070-44-0 73151030 11949646
43
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
44
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
45
Azathioprine Approved Phase 4 446-86-6 2265
46
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
47
Rifapentine Approved, Investigational Phase 4 61379-65-5 5462354
48
Ezetimibe Approved Phase 4 163222-33-1 150311
49
Pancrelipase Approved, Investigational Phase 4 53608-75-6 8519
50
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6

Interventional clinical trials:

(show top 50) (show all 4221)
# Name Status NCT ID Phase Drugs
1 A Pilot Study to Evaluate the Efficacy and Safety of Pegylated Interferon Alfa-2b Plus Ribavirin in the Treatment of Patients With Dual Chronic Hepatitis B and Delta Unknown status NCT00117533 Phase 4 pegylated IFN alfa-2b plus ribavirin
2 Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Hepatitis B e Antigen-positive Patients With Chronic Hepatitis B Unknown status NCT01906580 Phase 4 Peg-IFNα-2a;Entecavir
3 The Efficacy and Safety Study of Magnesium Isoglycyrrhizinate Injection Followed by Diammonium Glycyrrhizinate Enteric-coated Capsules and Combined With Entecavir on the Treatment of Chronic Hepatitis B Unknown status NCT03349008 Phase 4 Entecavir;Magnesium Isoglycyrrhizinate;Diammonium Glycyrrhizinate;Magnesium Isoglycyrrhizinate Placebo;Diammonium Glycyrrhizinate Placebo
4 Prospective, Multicenter, Randomized, and Comparative Clinical Trials to Compare the Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes Unknown status NCT04584242 Phase 4 gluconon tab 15mg;suganon tab 5mg
5 The Response and Outcomes of Pegylated Interferon Plus Ribavirin Combination Therapy for Chronic Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4 peginterferon alpha-2a and ribavirin
6 Phase IV Study of the Efficacy of Entecavir in Patients With Chronic Hepatitis B Virus Infection and Persistently Normal Alanine Aminotransferase Unknown status NCT01833611 Phase 4 Entecavir;placebo
7 Efficacy and Safety of Combination Therapy With Entecavir, Peginterferon Alfa-2b and Immunomodulators in Nucleoside or Nucleotide Analogue (NA)-Suppressed Chronic Hepatitis B Patients Unknown status NCT03332329 Phase 4 Entecavir;Granulocyte Macrophage Colony Stimulating Factor;Y peginterferon alfa-2b;HBV vaccine
8 Hepatitis C in Renal Transplant Recipients - Safety and Efficacy of a Conversion of Immunosuppression to High-dose Cyclosporine A and Its Impact on Hepatitis C Virus-replication, Parameters of Liver Function and Glucose Tolerance. An Open Label Trial. Unknown status NCT02108301 Phase 4 tacrolimus-cyclosporine A
9 A Single Center, Prospective Phase IV, Open-Label, Randomized Trial Comparing the Efficacy , Tolerability, and Safety of Quadritherapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide + Alfacalcidol ( Bon-One ®) ) Versus Triple Therapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide) Versus the Standard of Care Regimen(Reiferon Retard® + Ribavirin) in the Treatment of Naïve Chronic Hepatitis- C Among the Egyptian Population. Effectiveness Will be Evaluated Based on Sustained Viral Response (SVR) Unknown status NCT01896609 Phase 4 Bon one in Arm 3;Xerovirinc in Arm 2;Ribavirin in Arm 1
10 The Optimizing Treatment of Peginterferon Alpha in Chronic Hepatitis B Patients With Low Level HBsAg(I-Cure-3X) Unknown status NCT03801538 Phase 4 Peginterferon Alfa;Nucleoside Analog (Substance)
11 Sustained Off-treatment Response After HBeAg Loss in HBeAg-Pos Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues Unknown status NCT01911156 Phase 4 Continue NA treatment;Discontinue NA Treatment
12 A Randomized, Double Blind Controlled Trial to Evaluate the Therapeutic Effect of Telbivudine With or Without Prednisolone Priming in Patients With Chronic Hepatitis B Unknown status NCT00778596 Phase 4 Prednisolone;Placebo priming
13 Investigation on Antiviral Therapy of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B Patients Based on Detection of Interferon Gene Mutation and Interferon Receptor Unknown status NCT02973646 Phase 4 Entecavir or Tenofovir;Peginterferon Alfa-2B
14 A Real-World Study of Sequential Combination Therapy With Pegylated Interferon In Nucleoside-treated Patients With Chronic Hepatitis B Unknown status NCT03357822 Phase 4 Pegylated interferon;Entecavir;Tenofovir disoproxil fumarate
15 The Optimizing Treatment of PegIFN Alfa in HBeAg-negative Chronic Hepatitis B Patients With Low Level HBsAg Unknown status NCT02745704 Phase 4 Peginterferon alfa
16 Pegasys Plus Entecavir Versus Entecavir Versus Pegasys for Hepatitis B e Antigen-Negative Chronic Hepatitis B Unknown status NCT01925820 Phase 4 Pegasys&Entecavir
17 Open Label Study of Nucleus(t)Ide Treated Patients Randomised to Tenofovir, or Tenofovir + Telbivudine Unknown status NCT02774837 Phase 4 Tenofovir disoproxil;Telbivudine
18 Safety and Effect of Elbasvir/Grazoprevir Combination Therapy in Hemodialysis Patients With Chronic Hepatitis C Unknown status NCT03022006 Phase 4 elbasvir, grazoprevir
19 Randomized Study Comparing Nucleoside Analogues Plus Tenofovir and Nucleoside Analogues Plus Adefovir in Chronic Hepatitis B Patients With Suboptimal Response to Adefovir-based Combination Therapy Due to Nucleoside Analogues Resistance Unknown status NCT01595633 Phase 4 Switching from adefovir (10mg/day) to tenofovir (300mg/day)
20 A Study of Efficacy and Safety of Telbivudine in Pregnancy for the Prevention of Perinatal Transmission of Hepatitis B Virus Infection Unknown status NCT00939068 Phase 4 Telbivudine
21 A Prospective, Open-label, Multicenter Study of Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents Unknown status NCT02337127 Phase 4 Lamivudine
22 The Changes of CD8+T Cells Frequency and Function During Pegylated Interferon α-2a and Nucleoside Analogues Treatment in Patients With Chronic Hepatitis B Unknown status NCT03209037 Phase 4 Peginterferon Alfa-2a
23 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients-A Randomized, Double-Blinded, Controlled Trial Unknown status NCT01148576 Phase 4 entecavir;essentiale + entecavir;Vitamin E + entecavir
24 Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B Unknown status NCT00597259 Phase 4 Pegasys plus Entecavir;Entecavir
25 A Multicenter, Open-label, Prospective Study to Evaluate Antiviral Efficacy and Safety of Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection Unknown status NCT01594905 Phase 4 Entecavir + Tenofovir (MDR group)
26 Efficacies of Entecavir Add on HBeAg Negative Chronic Hepatitis B Patients With HBV DNA Load ≥1000 Copies/ml After 3 Months of Peginterferon Alpha 2a Treatment Unknown status NCT02365402 Phase 4 Entecavir
27 An Open-label Rollover Study in Chinese Patients After Finishing a 3-year Randomize Trial for Chronic Hepatitis B With High Serum Viral Load But Mild Elevated Aminotransferase Unknown status NCT02463019 Phase 4 Tenofovir Disoproxil Fumarate
28 The Efficacy and Safety of the Anti Hepatitis B Placenta Transfer Factor Injection in the Treatment of HBeAg Positive Chronic Hepatitis B, Randomized, Double Blind, Placebo Controlled, Multi Center Clinical Trial Unknown status NCT02412319 Phase 4 Anti-HBV placenta transfer factor injection
29 Open, Randomized and Multicenter Phase IV Study to Compare the Efficacy and Safety of Two Different Treatments Duration 24 Versus 48 Weeks in Chronic Hepatitis C Genotypes 2 and/or 3 co-Infected HIV-HCV Patients. Unknown status NCT00611819 Phase 4 Peg interferon + Ribavirin
30 Maintaining Antiviral Efficacy After Switching to Generic Entecavir, Baracle® in Patients Taking Baraclude® 1 mg for Antiviral Resistant Chronic Hepatitis B; A Noninferiority Study Assessing Non-detection Rate of Hepatitis B Virus DNA Unknown status NCT04069858 Phase 4 Switching to Generic Entecavir (Baracle®)
31 Efficacy and Safety of a Hansenula-derived Pegylated Interferon α2a (Reiferon Retard®) in Treatment of Patients With Chronic Hepatitis C Virus Infection: A National Multi-center Phase IV Open Label Non-Randomized Trial Unknown status NCT01649245 Phase 4 Reiferon retard
32 HBsAg Clearance of Peginterferon Treatment in Patients Who Had Chronic Hepatitis B and Were on the Treatment of Nucleoside(Acid) Analogues Unknown status NCT02362490 Phase 4 peginterferon alpha 2a
33 The Changes of CD4+T Cells Frequency and Function During Pegylated Interferon α-2a and Nucleoside Analogues Treatment in Patients With Chronic Hepatitis B Unknown status NCT03209011 Phase 4 Peginterferon Alfa-2a
34 The Changes of Natural Killer Cells Frequency and Function During Pegylated Interferon α-2a and Nucleoside Analogues Treatment in Patients With Chronic Hepatitis B. Unknown status NCT03208998 Phase 4 Peginterferon Alfa-2a
35 Comparison of Antiviral Efficacy of Entecavir Monotherapy and Combination Treatment With Poly IC for Chronic Hepatitis B Unknown status NCT02532413 Phase 4 Poly IC;Entecavir
36 PhaseIVstudy to Evaluate the Non-inferiority of Cavir®Tab. in Terms of Hepatitis B Virus(HBV)DNA Undetectability Comparing Baraclude® Tab. in Hepatitis B e Antigen(HBeAg)(+) Chronic Hepatitis B Patients Treated With Long-term Baraclude® Tab Unknown status NCT02523547 Phase 4 Cavir;Baraclude
37 An Open-label, Multi-center, Randomized Study Comparing the Effects of Oral Hypoglycemic Agents on Viral Kinetics of Chronic Hepatitis C Patients Receiving Pegylated Interferon Alfa 2b Plus Ribavirin Unknown status NCT01025765 Phase 4 Pioglitazone;Acarbose;Metformin
38 Study to Identify Eligible Subjects Using Response Guided Therapy-Stopping Rule for Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults. Unknown status NCT02822547 Phase 4 Peginterferon alfa-2a
39 Treatment of Chronic Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels With Peginterferon α-2a (40 kDa) Plus Ribavirin Unknown status NCT00575627 Phase 4 Peg-Interferon alpha2a plus Ribavirin
40 A Prospective Randomized, Open Labeled, Phase IV, Multicenter Study for Peginterferon Alfa-2a and Weight-based Ribavirin for 16 or 24 Weeks in genotype2 Chronic Hepatitis C Patients Who Achieved Rapid Virologic Response Unknown status NCT01056172 Phase 4 Peginterferon alfa-2a and Ribavirin
41 HBsAg Loss/Seroconversion in Low Replicative Chronic HBV Infection Patients With Low Level HBsAg Treated With Peginterferon Alpha Unknown status NCT02908763 Phase 4 peginterferon alfa
42 The Optimizing Treatment of Peginterferon Alpha in HBeAg-negative Chronic Hepatitis B Virus Patients With Low Level HBsAg Unknown status NCT02893124 Phase 4 peginterferon alfa
43 A Multi-center, Open Label, Randomized Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Capsule Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Unknown status NCT01436539 Phase 4 Adefovir Dipivoxil and polyene phosphatidylcholine;Adefovir Dipivoxil
44 A Pilot Study to Treat Patients With Chronic HCV Genotype 1 and ESRD Receiving Hemodialysis and Naïve to Prior HCV Therapy With Peginterferon Alfa-2b, the Maximally Tolerated Ribavirin Dose and Boceprevir Unknown status NCT01731301 Phase 4 Ribavirin;Peginterferon;Boceprevir
45 Randomized Trial of Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients Who Have Undergone Lamivudine/Adefovir Add-on Treatment Unknown status NCT01491295 Phase 4 Tenofovir disoproxil fumarate;Lamivudine plus adefovir
46 A Multi-center, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Generic Entecavir Monotherapy or in Combination With Adefovir for Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Unknown status NCT01341743 Phase 4 Entecavir;Entecavir, Adefovir
47 Clinical Study of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B Unknown status NCT01380951 Phase 4 telbivudine
48 A Randomized, Open-label, Multi-center Clinical Trial to Evaluate Addition of Peginterferon Alfa-2a to CHB Patients Treated With NAs and Achieved HBV DNA<15 IU/ml、HBeAg<100 PEIU/ml、HBsAg Positive and HBsAg<1500 IU/ml. Unknown status NCT02894918 Phase 4 Peginterferon alfa-2a
49 A Randomized, Prospective, Multicenter, Open-label Study to Evaluate the Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir in HBeAg-positive Chronic Hepatitis B Patients Unknown status NCT01588912 Phase 4 Telbivudine;Tenofovir;Entecavir
50 A Randomized, Multi-center, Phase IV Open-label Study Evaluating the Antiviral Efficacy of Addition of Vitamin D in Patients With Treatment Naïve Chronic Hepatitis C Receiving Peginterferon Alfa-2a Plus Ribavirin Unknown status NCT01439776 Phase 4

Search NIH Clinical Center for Hepatitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


ASTRAGALUS EXTRACT PWDR
Astragalus preparation
Milk thistle extract

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hepatitis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hepatitis:
Promethera HepaStem, human adult liver progenitor cells for liver diseases
Embryonic/Adult Cultured Cells Related to Hepatitis:
Adult liver progenitor cells PMIDs: 22525602 23211283 24142276 22900053 19091822

Cochrane evidence based reviews: hepatitis, chronic

Sources

Genetic Tests for Hepatitis

About this section

Genetic tests related to Hepatitis:

# Genetic test Affiliating Genes
1 Hepatitis 28
Sources

Anatomical Context for Hepatitis

About this section

Organs/tissues related to Hepatitis:

MalaCards : Liver, Kidney, T Cells, Skin, Bone Marrow, Myeloid, Placenta
Sources

Publications for Hepatitis

About this section

Articles related to Hepatitis:

(show top 50) (show all 54598)
# Title Authors PMID Year
1
Early prediction model for prognosis of patients with hepatitis-B-virus-related acute-on-chronic liver failure received glucocorticoid therapy. 41
36376930 2022
2
Association between the risk of hepatitis virus-related hepatocellular carcinoma and EGF polymorphism: A PRISMA-compliant updated meta-analysis. 41
36281156 2022
3
Prediction of Hepatitis disease using ensemble learning methods. 41
36415304 2022
4
NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. 53 62
20392357 2010
5
Differential transcriptional responses to interferon-alpha and interferon-gamma in primary human hepatocytes. 53 62
20038212 2010
6
Treatment of chronic hepatitis E in liver transplant recipients with pegylated interferon alpha-2b. 53 62
20373458 2010
7
Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum ALT during lamivudine treatment. 53 62
19788696 2010
8
+49G > A polymorphism in the cytotoxic T-lymphocyte antigen-4 gene increases susceptibility to hepatitis B-related hepatocellular carcinoma in a male Chinese population. 53 62
19778566 2010
9
Usefulness of non-invasive markers for predicting liver cirrhosis in patients with chronic hepatitis B. 53 62
19793171 2010
10
Impaired TLR3/IFN-beta signaling in monocyte-derived dendritic cells from patients with acute-on-chronic hepatitis B liver failure: relevance to the severity of liver damage. 53 62
19833099 2009
11
Myeloid STAT3 inhibits T cell-mediated hepatitis by regulating T helper 1 cytokine and interleukin-17 production. 53 62
19686746 2009
12
Prevalence of hepatitis E virus infection in liver transplant recipients. 53 62
19790147 2009
13
[Gene polymorphism of transforming growth factor beta1 (TGF-beta1) in the pathogenesis and clinical course of chronic hepatitis in children]. 53 62
20081262 2009
14
[Role of transforming growth factor beta1 (TGF-beta1) in the pathogenesis and clinical course of chronic hepatitis in children]. 53 62
20081261 2009
15
[A study on the treatment of chronic hepatitis B with YMDD mutation]. 53 62
19335977 2009
16
Chromogranin A levels in chronic liver disease and hepatocellular carcinoma. 53 62
18762462 2009
17
Correlation between humoral and cellular immune responses and the expression of the hepatitis A receptor HAVcr-1 on T cells after hepatitis A re-vaccination in high and low-responder vaccinees. 53 62
18996424 2009
18
[Treatment with pegylated interferon and ribavirin in a patient with fibrosing cholestatic hepatitis due to recurrent hepatitis C after liver transplantation]. 53 62
19119247 2008
19
[Hepatic steatosis: a common reason for elevated alanine aminotransferase levels in HBsAg-positive chronic hepatitis B patients with low HBV DNA loads]. 53 62
19032864 2008
20
Serum neopterin levels in children with hepatitis-B-related chronic liver disease and its relationship to disease severity. 53 62
19058311 2008
21
High values of CXCL10 serum levels in mixed cryoglobulinemia associated with hepatitis C infection. 53 62
18775023 2008
22
Can serum TGF-beta 1 be used to evaluate the response to antiviral therapy of haemophilic patients with HCV-related chronic hepatitis? 53 62
19144287 2008
23
[A case study: interferon-beta-induced remission of ulcerative colitis in a patient with type C chronic hepatitis]. 53 62
18772577 2008
24
Dietary amino acid taurine ameliorates liver injury in chronic hepatitis patients. 53 62
17690950 2008
25
A prospective and comparative cohort study on efficacy and drug resistance during long-term lamivudine treatment for various stages of chronic hepatitis B and cirrhosis. 53 62
18086120 2008
26
Detection of HBV core promoter and precore mutations helps distinguish flares of chronic hepatitis from acute hepatitis B. 53 62
18410611 2008
27
Markers for hepatitis A, B and C in methadone maintained patients: an unexpectedly high co-infection with silent hepatitis B. 53 62
18339114 2008
28
Measurement of serum branched-chain amino acids to tyrosine ratio level is useful in a prediction of a change of serum albumin level in chronic liver disease. 53 62
18021234 2008
29
[Hereditary hemochromatosis, alpha-1-antitrypsin deficiency and Wilson's disease. Pathogenesis, clinical findings and pathways to diagnosis]. 53 62
18210110 2008
30
Identification of hepatocellular-carcinoma-associated antigens and autoantibodies by serological proteome analysis combined with protein microarray. 53 62
18161940 2008
31
Characterization of HBeAg-negative chronic hepatitis B in western Brazilian Amazonia. 53 62
18553011 2008
32
Intake of purple sweet potato beverage affects on serum hepatic biomarker levels of healthy adult men with borderline hepatitis. 53 62
17299464 2008
33
The efficacy of short-term interferon-beta therapy for chronic hepatitis C patients with low virus load. 53 62
18310963 2008
34
Long-term lamivudine treatment of children with chronic hepatitis B: durability of therapeutic responses and safety. 53 62
18088241 2008
35
[An analysis of the clinical characteristics of patients with chronic hepatitis B superinfected with acute hepatitis E]. 53 62
18322591 2007
36
Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection. 53 62
17705189 2007
37
Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive chronic hepatitis B. 53 62
17607775 2007
38
[Expression of K18, Ser-33 and Ser-52 phosphorylated K18 in HBV infected human liver disease and its significance]. 53 62
17971926 2007
39
Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. 53 62
17596875 2007
40
DNA methyltransferase expression and DNA methylation in human hepatocellular carcinoma and their clinicopathological correlation. 53 62
17549390 2007
41
Chronic hepatitis B virus carriers in the immunotolerant phase of infection: histologic findings and outcome. 53 62
17428739 2007
42
Serum CXCL10 levels and occurrence of thyroid dysfunction in patients treated with interferon-alpha therapy for hepatitis C virus-related hepatitis. 53 62
17389454 2007
43
What is the reason of elevated alanine aminotransferase level in HBeAg negative patients with low viremia: NAFLD or chronic hepatitis? 53 62
17519831 2007
44
Significance of hepatitis B virus surface antigen, hepatitis C virus expression in hepatocellular carcinoma and pericarcinomatous tissues. 53 62
17465484 2007
45
Changing patterns of acute viral hepatitis at a major urban referral center in Egypt. 53 62
17243045 2007
46
A mutation in the interferon sensitivity-determining region is associated with responsiveness to interferon-ribavirin combination therapy in chronic hepatitis patients infected with a Japan-specific subtype of hepatitis C virus genotype 1B. 53 62
17133546 2007
47
Response to interferon-alpha in chronic hepatitis B patients with and without precore mutant strain and effects on HBsAg titers. 53 62
17934260 2007
48
Interferon therapy improves the irregular regeneration of hepatocytes in liver in patients with C-viral chronic hepatitis and liver cirrhosis. 53 62
17191016 2007
49
High frequency of hepatocellular carcinoma in Mongolia; association with mono-, or co-infection with hepatitis C, B, and delta viruses. 53 62
17063518 2006
50
Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. 53 62
17133585 2006
Sources

Variations for Hepatitis

About this section

ClinVar genetic disease variations for Hepatitis:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 MT-TL1 NC_012920.1:m.3275C>T SNV Uncertain Significance
 370045 rs1057516057 GRCh37: MT:3275-3275
GRCh38: MT:3275-3275

Copy number variations for Hepatitis from CNVD:

6
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 226111 7 55054218 55242525 Amplification EGFR Hepatitis
Sources

Expression for Hepatitis

About this section
Search GEO for disease gene expression data for Hepatitis.
Sources

Pathways for Hepatitis

About this section

Pathways related to Hepatitis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Toll-like receptor signaling pathway 74
Show member pathways
 11.75 SLC10A1 IFNA2 IFNA1 DDX3X CLEC4M
2
Ebola virus infection in host 74
11.44 HAVCR2 HAVCR1 CLEC4M
3
Cholestasis 74
10.21 SLC10A1 SCARB1
Sources

GO Terms for Hepatitis

About this section

Biological processes related to Hepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 viral entry into host cell GO:0046718 9.23 SLC10A1 SCARB1 HAVCR1 CLEC4M
2 biological process involved in interspecies interaction between organisms GO:0044419 8.96 CLEC4M ASGR2

Molecular functions related to Hepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 virus receptor activity GO:0001618 9.23 SLC10A1 SCARB1 HAVCR1 CLEC4M
Sources

Sources for Hepatitis

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....